Florian Putz1, Jan Müller2, Caterina Wimmer2, Nicole Goerig2, Stefan Knippen2, Heinrich Iro3, Philipp Grundtner3, Ilker Eyüpoglu4, Karl Rössler4, Sabine Semrau2, Rainer Fietkau2, Sebastian Lettmaier2. 1. Department of Radiation Oncology, Friedrich-Alexander-University Erlangen-Nuremberg, Universitaetsstraße 27, 91054, Erlangen, Germany. florian.putz@uk-erlangen.de. 2. Department of Radiation Oncology, Friedrich-Alexander-University Erlangen-Nuremberg, Universitaetsstraße 27, 91054, Erlangen, Germany. 3. Department of Otorhinolaryngology-Head and Neck Surgery, Friedrich-Alexander-University Erlangen-Nuremberg, Waldstraße 1, 91054, Erlangen, Germany. 4. Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage 6, 91054, Erlangen, Germany.
Abstract
OBJECTIVE: The aim of this publication is to present long-term data on functional outcomes and tumor control in a cohort of 107 patients treated with stereotactic radiotherapy (RT) for vestibular schwannoma. PATIENTS AND METHODS: Included were 107 patients with vestibular schwannoma (primary or recurrent following resection) treated with stereotactic RT (either fractioned or single-dose radiosurgery) between October 2002 and December 2013. Local control and functional outcomes were determined. Analysis of hearing preservation was limited to a subgroup of patients with complete audiometric data collected before treatment and during follow-up. Vestibular function test (FVT) results could be analyzed in a subset of patients and were compared to patient-reported dizziness. RESULTS: After a mean follow-up of 46.3 months, actuarial local control for the whole cohort was 100% after 2, 97.6% after 5, and 94.1% after 10 years. In patients with primary RT, serviceable hearing was preserved in 72%. Predictors for preservation of serviceable hearing in multivariate analysis were time of follow-up (odds ratio, OR = 0.93 per month; p = 0.021) and pre-RT tumor size (Koos stage I-IIa vs. IIb-IV; OR = 0.15; p = 0.031). Worsening of FVT results was recorded in 17.6% (N = 3). Profound discrepancy of patient-reported dizziness and FVT results was observed after RT. In patients with primary RT, worsening of facial nerve function occurred in 1.7% (N = 1). CONCLUSION: Stereotactic RT of vestibular schwannoma provides good functional outcomes and high control rates. Dependence of hearing preservation on time of follow-up and initial tumor stage has to be considered.
OBJECTIVE: The aim of this publication is to present long-term data on functional outcomes and tumor control in a cohort of 107 patients treated with stereotactic radiotherapy (RT) for vestibular schwannoma. PATIENTS AND METHODS: Included were 107 patients with vestibular schwannoma (primary or recurrent following resection) treated with stereotactic RT (either fractioned or single-dose radiosurgery) between October 2002 and December 2013. Local control and functional outcomes were determined. Analysis of hearing preservation was limited to a subgroup of patients with complete audiometric data collected before treatment and during follow-up. Vestibular function test (FVT) results could be analyzed in a subset of patients and were compared to patient-reported dizziness. RESULTS: After a mean follow-up of 46.3 months, actuarial local control for the whole cohort was 100% after 2, 97.6% after 5, and 94.1% after 10 years. In patients with primary RT, serviceable hearing was preserved in 72%. Predictors for preservation of serviceable hearing in multivariate analysis were time of follow-up (odds ratio, OR = 0.93 per month; p = 0.021) and pre-RT tumor size (Koos stage I-IIa vs. IIb-IV; OR = 0.15; p = 0.031). Worsening of FVT results was recorded in 17.6% (N = 3). Profound discrepancy of patient-reported dizziness and FVT results was observed after RT. In patients with primary RT, worsening of facial nerve function occurred in 1.7% (N = 1). CONCLUSION: Stereotactic RT of vestibular schwannoma provides good functional outcomes and high control rates. Dependence of hearing preservation on time of follow-up and initial tumor stage has to be considered.
Entities:
Keywords:
Audiometry; Dizziness; Hearing loss; Radiosurgery; Vestibular function tests
Authors: Jean Régis; William Pellet; Christine Delsanti; Henry Dufour; Pierre Hughes Roche; Jean Marc Thomassin; Michel Zanaret; Jean Claude Peragut Journal: J Neurosurg Date: 2002-11 Impact factor: 5.115
Authors: Carys Thomas; Salvatore Di Maio; Roy Ma; Emily Vollans; Christina Chu; Brenda Clark; Richard Lee; Michael McKenzie; Montgomery Martin; Brian Toyota Journal: J Neurosurg Date: 2007-11 Impact factor: 5.115
Authors: John M Lasak; Darren Klish; Thomas C Kryzer; Chris Hearn; John P Gorecki; Grant P Rine Journal: Otol Neurotol Date: 2008-12 Impact factor: 2.311
Authors: Julian P Sauer; Thomas M Kinfe; Bogdan Pintea; Andreas Schäfer; Jan P Boström Journal: Strahlenther Onkol Date: 2018-05-23 Impact factor: 3.621
Authors: Sergiu Scobioala; Ross Parfitt; Peter Matulat; Christopher Kittel; Fatemeh Ebrahimi; Heidi Wolters; Antoinette Am Zehnhoff-Dinnesen; Hans Theodor Eich Journal: Strahlenther Onkol Date: 2017-09-08 Impact factor: 3.621
Authors: Dominik Oft; Manuel Alexander Schmidt; Thomas Weissmann; Johannes Roesch; Veit Mengling; Siti Masitho; Christoph Bert; Sebastian Lettmaier; Benjamin Frey; Luitpold Valentin Distel; Rainer Fietkau; Florian Putz Journal: Front Oncol Date: 2021-01-08 Impact factor: 6.244
Authors: Maike Küchler; Rami A El Shafie; Sebastian Adeberg; Klaus Herfarth; Laila König; Kristin Lang; Juliane Hörner-Rieber; Peter Karl Plinkert; Wolfgang Wick; Felix Sahm; Simon David Sprengel; Jürgen Debus; Denise Bernhardt Journal: Cancers (Basel) Date: 2022-04-10 Impact factor: 6.575